October 10, 2017
Clinical Data Demonstrate Favorable Safety, Tolerability and Pharmacokinetics Additional Nonclinical Data Show APX001 is Effective Against a Broad Range of Pathogenic Fungi, Including Deadly Candida auris SAN DIEGO – October 9, 2017 – Amplyx Pharmaceuticals, a company developing novel antimicrobial agents for life-threatening fungal infections, today announced that it presented results from two Phase 1 studies of APX001,...


Robust operating profit and record level of funds for grants
18. April 2018
The Lundbeck Foundation enters partnership with
10. April 2018
Four neuroscientists receive The Brain Prize for crucial research on Alzheimer’s
6. March 2018


Lundbeckfonden Ventures

Lundbeckfonden Emerge